| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2326-6066.CIR-13-0028 |
| P8608 | Fatcat ID | release_jjuttr3ktjdovmhb4rikl77bhy |
| P932 | PMC publication ID | 3881271 |
| P698 | PubMed publication ID | 24409449 |
| P2093 | author name string | Li Shen | |
| Kenneth Aldape | |||
| Mark Gilbert | |||
| Ganesh Rao | |||
| Jun Wei | |||
| Arvind Rao | |||
| Amy B Heimberger | |||
| Tiffany Doucette | |||
| Kristine Dziurzynski | |||
| P2860 | cites work | Annexin-1 modulates T-cell activation and differentiation | Q24305148 |
| The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors | Q24631515 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values | Q30955425 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics | Q33648189 | ||
| IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways | Q33888307 | ||
| Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway | Q34129168 | ||
| IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis | Q34389464 | ||
| Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses | Q34393758 | ||
| Immune genes are associated with human glioblastoma pathology and patient survival. | Q34415093 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Macrophages regulate the angiogenic switch in a mouse model of breast cancer | Q34582812 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | Q34764143 | ||
| Glioma cancer stem cells induce immunosuppressive macrophages/microglia | Q34992518 | ||
| An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme | Q35800650 | ||
| Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma | Q36179166 | ||
| Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma | Q36627165 | ||
| The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. | Q37020840 | ||
| Differentiation-induced post-transcriptional control of B7-H1 in human trophoblast cells | Q37345217 | ||
| Molecular subclassification of diffuse gliomas: seeing order in the chaos | Q37858944 | ||
| Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment | Q37970682 | ||
| Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. | Q39765588 | ||
| Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity | Q40351340 | ||
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment | Q40400501 | ||
| Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma | Q41773542 | ||
| The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses | Q41779891 | ||
| IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo | Q42139164 | ||
| Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation. | Q42713659 | ||
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 | ||
| Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. | Q47948464 | ||
| Glycosilated nucleolin as marker for human gliomas. | Q48883976 | ||
| Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. | Q48973528 | ||
| CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion | Q51752454 | ||
| Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. | Q55469941 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat | Q71572143 | ||
| ICOS-Dependent Homeostasis and Function of Foxp3+ Regulatory T Cells in Islets of Nonobese Diabetic Mice | Q83194001 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| heterogeneity | Q928498 | ||
| The Cancer Genome Atlas | Q3979425 | ||
| P304 | page(s) | 112-122 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Cancer Immunology Research | Q26841983 |
| P1476 | title | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | |
| P478 | volume | 1 |
| Q38806032 | A Zebrafish Live Imaging Model Reveals Differential Responses of Microglia Toward Glioblastoma Cells In Vivo |
| Q52659572 | Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. |
| Q58093339 | Blood handling and leukocyte isolation methods impact the global transcriptome of immune cells |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q96952153 | CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma |
| Q58766544 | CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas |
| Q38203815 | CNS macrophages and peripheral myeloid cells in brain tumours |
| Q92481361 | CTLA-4 correlates with immune and clinical characteristics of glioma |
| Q38838646 | Checkpoint inhibition in meningiomas |
| Q36582785 | Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus |
| Q39937053 | Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas |
| Q28084351 | Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? |
| Q36200301 | Conservation of immune gene signatures in solid tumors and prognostic implications. |
| Q33786677 | Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity. |
| Q36946604 | Control of glioma cell migration and invasiveness by GDF-15 |
| Q38834470 | Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. |
| Q64286968 | DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma |
| Q46586294 | Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma |
| Q47965779 | Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma |
| Q38743138 | Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. |
| Q55459936 | Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. |
| Q37040756 | Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire |
| Q97069912 | GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models |
| Q26859782 | Glioblastoma cancer stem cells: Biomarker and therapeutic advances |
| Q38868808 | Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype |
| Q47790600 | Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted |
| Q58617308 | Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis |
| Q58609492 | Harnessing the immune system in glioblastoma |
| Q33656811 | History and current state of immunotherapy in glioma and brain metastasis |
| Q47103832 | IDH mutational status and the immune system in gliomas: a tale of two tumors? |
| Q90329713 | IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma |
| Q35610772 | Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance |
| Q37687506 | Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference |
| Q55261256 | Immune Microenvironment in Glioblastoma Subtypes. |
| Q38691992 | Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma |
| Q55115778 | Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. |
| Q55457206 | Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. |
| Q64932321 | Immune infiltration, glioma stratification, and therapeutic implications. |
| Q91797935 | Immune landscapes associated with different glioblastoma molecular subtypes |
| Q59794242 | Immunogenetics of glioblastoma: the future of personalized patient management |
| Q36224048 | Immunosuppressive mechanisms in glioblastoma |
| Q92783338 | Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response |
| Q90323312 | Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment |
| Q31113520 | Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma |
| Q34427910 | Master regulators, regulatory networks, and pathways of glioblastoma subtypes |
| Q57116103 | Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway |
| Q36785139 | MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints |
| Q42969286 | MicroRNAs as novel immunotherapeutics |
| Q38243193 | Molecular heterogeneity of glioblastoma and its clinical relevance |
| Q52691329 | New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection |
| Q64100758 | Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma |
| Q39043417 | Novel vaccines for glioblastoma: clinical update and perspective |
| Q57280843 | Osteopontin mediates glioblastoma-associated macrophage infiltration and is a therapeutic target |
| Q49359656 | PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations |
| Q47199921 | PD-1 related transcriptome profile and clinical outcome in diffuse gliomas |
| Q36493843 | PD-L1 expression and prognostic impact in glioblastoma |
| Q48429982 | Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma |
| Q35815273 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma |
| Q28081371 | Prospects of immune checkpoint modulators in the treatment of glioblastoma |
| Q92881504 | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma |
| Q52699628 | SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. |
| Q39326147 | Sample Level Enrichment Analysis of KEGG Pathways Identifies Clinically Relevant Subtypes of Glioblastoma |
| Q36060357 | Several immune escape patterns in non-Hodgkin's lymphomas. |
| Q64004325 | Subgroup-specific immune and stromal microenvironment in medulloblastoma |
| Q38557236 | The Dynamics of Interactions Among Immune and Glioblastoma Cells |
| Q38652319 | The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells |
| Q39294814 | The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses |
| Q55456739 | The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. |
| Q38363102 | The role of STAT3 in tumor-mediated immune suppression |
| Q42577764 | Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression |
| Q99240665 | Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival |
| Q55457248 | Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma. |
| Q46410671 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. |
| Q47102313 | Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. |
| Q38647050 | Tumor-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumor subtype. |
| Q38243975 | Vaccine therapies for patients with glioblastoma |
Search more.